Silvia I. Vanzulli

Silvia I. Vanzulli

Auto-generated profile, based on publicly available information

Silvia I. Vanzulli

Instituto de Biología y Medicina Experimental (IBYME), CONICET Buenos Aires Argentina

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
AEAndrés Elía
Andrés Elía
LSLeo Saldain
Leo Saldain
SVSilvia I. Vanzulli
Silvia I. Vanzulli
Luisa A. HelgueroLuisa A. Helguero
Luisa A. Helguero
CLCaroline A. Lamb
Caroline A. Lamb
CLClaudia Lanari
Claudia Lanari
Purpose: Preclinical data suggest that antiprogestins inhibit the growth of luminal breast carcinomas that express higher levels of progesterone receptor isoform A (PRA) than isoform B (PRB). Thus, we designed a presurgical window of opportunity trial to determine the therapeutic effects of mifepristone in patients with breast cancer, based on their high PRA/PRB isoform ratio (MIPRA; NCT02651844). Patients and Methods: Twenty patients with luminal breast carcinomas with PRA/PRB > 1.5 (determined by Western blots), and PR ≥ 50%, naïve from previous treatment, were included for mifepristone treatment (200 mg/day orally; 14 days). Core needle biopsies and surgical samples were formalin fixed for IHC studies, while others were snap-frozen to perform RNA sequencing (RNA-seq), proteomics, and/or Western blot studies. Plasma mifepristone levels were determined using mass spectrometry. The primary endpoint was the comparison of Ki67 expression pretreatment and posttreatment. Results: A 49.62% decrease in Ki67 staining was observed in all surgical specimens compared with baseline (P = 0.0003). Using the prespecified response parameter (30% relative reduction), we identified 14 of 20 responders. Mifepristone induced an increase in tumor-infiltrating lymphocytes; a decrease in hormone receptor and pSer118ER expression; and an increase in calregulin, p21, p15, and activated caspase 3 expression. RNA-seq and proteomic studies identified downregulated pathways related to cell proliferation and upregulated pathways related to immune bioprocesses and extracellular matrix remodeling. Conclusions: Our results support the use of mifepristone in patients with luminal breast cancer with high PRA/PRB ratios. The combined effects of mifepristone and estrogen receptor modulators warrant clinical evaluation to improve endocrine treatment responsiveness in these patients. See related commentary by Ronchi and Brisken, p. 833

29 July 2016 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
FHFuad Huamán‐Garaicoa
Fuad Huamán‐Garaicoa
ARAlejandro Roisman
Alejandro Roisman
MAMariana Arias
Mariana Arias
CTCarla Trila
Carla Trila
MFMiguel Fridmanis
Miguel Fridmanis
ISIrma Slavutsky
Irma Slavutsky

28 December 2024 in International Journal of Cancer
Verified
Journal Article
Closed access
MRMaría S. Rodriguez
María S. Rodriguez
YMYamil Mahmoud
Yamil Mahmoud
SVSilvia Vanzulli
Silvia Vanzulli
SGSebastián Giulianelli
Sebastián Giulianelli
ESEunice Spengler
Eunice Spengler
CPCecilia Pérez Piñero
Cecilia Pérez Piñero


25 November 2025
Verified
Other
Open access
AEAndrés Elía
Andrés Elía
LSLeo Saldain
Leo Saldain
SVSilvia I. Vanzulli
Silvia I. Vanzulli
Luisa A. HelgueroLuisa A. Helguero
Luisa A. Helguero
CLCaroline A. Lamb
Caroline A. Lamb
CLClaudia Lanari
Claudia Lanari
Morphological evaluation of CNBs and matched surgical samples; RNA-Seq analysis; Proteomics

1 April 2023
Verified
Other
Open access
AEAndrés Elía
Andrés Elía
LSLeo Saldain
Leo Saldain
SVSilvia I. Vanzulli
Silvia I. Vanzulli
Luisa A. HelgueroLuisa A. Helguero
Luisa A. Helguero
CLCaroline A. Lamb
Caroline A. Lamb
CLClaudia Lanari
Claudia Lanari
Morphological evaluation of CNBs and matched surgical samples; RNA-Seq analysis; Proteomics